Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Peter G. Schnabel"'
Autor:
Robert A. Campbell, Angus John Morrison, Julia M. Adam, Daniel Ecker, Stuart Francis, James Baker, Anna-Marie Easson, Fiona Jeremiah, Ola Epemolu, Takao Kiyoi, Roberta Bursi, Duncan McArthur, Jurgen Schulz, Darren Edwards, Paul Passier, Maureen Deehan, Paul Westwood, Joanna Udo de Haes, Peter G. Schnabel, Jean E. Cottney, John K. Clark, Glenn Walker, Paul Harradine, Heinz Steinbrede, Paul Ratcliffe, Grant Wishart, Ruth Fields, Jack Pick, Louise Evans
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:2541-2546
We report an expansion of the structure-activity relationship (SAR) of a novel series of indole-3-heterocyclic CB1 receptor agonists. Starting from the potent but poorly soluble lead, 1, a rational approach was taken in order to balance solubility, h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bac4fce3568bffcc8bec0c8ef27a0ea4
https://doi.org/10.1016/j.bmcl.2011.02.023
https://doi.org/10.1016/j.bmcl.2011.02.023
Publikováno v:
Pharmacotherapy. 23:319-325
Study Objective. To assess the effects of food on the bioavailability of testosterone undecanoate, testosterone, and 5a-dihydrotestosterone (DHT) after administration of a new oral testosterone undecanoate formulation, Andriol Testocaps. Design. Rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6da65e6097b4050663504384e28613c7
https://doi.org/10.1592/phco.23.3.319.32104
https://doi.org/10.1592/phco.23.3.319.32104
Publikováno v:
Contraception. 58:283-288
Eight healthy women between 22 and 40 years of age participated in this prospective open study of 2 years' duration. Either on or between days 1 to 7 of a spontaneous menses, an intravenous bolus dose of 150 micrograms etonogestrel (3-ketodesogestrel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9245b6de45f4117f54a02d53b65da26
https://doi.org/10.1016/s0010-7824(98)00110-3
https://doi.org/10.1016/s0010-7824(98)00110-3
Publikováno v:
Contraception. 87(2)
BACKGROUND: The pharmacokinetics of the monophasic oral contraceptive nomegestrol acetate (NOMAC) plus 17beta-estradiol (E(2)) were investigated after a single dose and multiple dosing. STUDY DESIGN: NOMAC/E2 (2.5 mg/1.5 mg) was administered daily to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc35be3e7f2ddf10771cfc4900788546
https://pubmed.ncbi.nlm.nih.gov/22898360
https://pubmed.ncbi.nlm.nih.gov/22898360
Autor:
Peter G. Schnabel, Gabriele S. Merki-Feld, Ingrid Duijkers, Ellen Mommers, Alice Malvy, Michiel W. van den Heuvel
The etonogestrel (ENG)-releasing implant is a subdermal progestogen-only contraceptive that provides coverage for up to 3 years. This long-acting hormonal contraceptive has been available in Europe since 1998 and in the US since 2006. To date, locali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cf5c21bcabd787b00041c497794be0d
https://www.zora.uzh.ch/id/eprint/71899/
https://www.zora.uzh.ch/id/eprint/71899/
Publikováno v:
Pharmacotherapy. 23(10)
Study Objective. To assess the pharmacokinetic parameters of testosterone undecanoate after administration of a new oral formulation, Andriol Testocaps. Design. Randomized, open-label, group-comparative, parallel-design, dose-proportionality study. S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13f15d4808b644660b559991d5e33a09
https://pubmed.ncbi.nlm.nih.gov/14594344
https://pubmed.ncbi.nlm.nih.gov/14594344
Publikováno v:
Clinical Endocrinology
Objective Andriol® Testocaps® is a new oral formulation of testosterone undecanoate (TU) for treatment of hypogonadism. As TU is taken up by the intestinal lymphatic system, both the presence and the composition of food influence the absorption. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ea13077607bbe2a5a848dee6dcd0ce2
https://doi.org/10.1111/j.1365-2265.2007.02781.x
https://doi.org/10.1111/j.1365-2265.2007.02781.x